[⁶⁸Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [¹⁷⁷Lu]Lu-PSMA-617 treatment.

ABSTRACT:

Introduction

Patient eligibility for [¹⁷⁷Lu]Lu-PSMA therapy remains a challenge, with only 40-60% response rate when patient selection is done based on the lesion uptake (SUV) on [⁶⁸Ga]Ga-PSMA-PET/CT. Prediction of absorbed dose based on this pre-treatment scan could improve patient selection and help to individualize treatment by maximizing the absorbed dose to target lesions while adhering to the threshold doses for the organs at risk (kidneys, salivary glands, and liver).

Methods

Ten patients with low-volume hormone-sensitive prostate cancer received a pre-therapeutic [⁶⁸Ga]Ga-PSMA-11 PET/CT, followed by 3 GBq [¹⁷⁷Lu]Lu-PSMA-617 therapy. Intra-therapeutically, SPECT/CT was acquired at 1, 24, 48, 72, and 168 h. Absorbed dose in o

SUBMITTER: Peters SMB 

PROVIDER: S-EPMC8921092 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature